Protective effects of bifidobacterial strains against toxigenic Clostridium difficile

Frontiers in Microbiology

Volumn 9, Issue MAY, 2018, Pages

  Wei, Yanxia ^a   Yang, Fan ^a   Wu, Qiong ^a   Gao, Jing ^a   Liu, Wenli ^a   Liu, Chang ^b   Guo, Xiaokui ^b   Suwal, Sharmila ^a   Kou, Yanbo ^a   Zhang, Bo ^a   Wang, Yugang ^a   Zheng, Kuiyang ^a   Tang, Renxian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bifidobacterium; Clostridium difficile; Degradation; Probiotics; Protective effect; Toxin A; Toxin B

Indexed keywords

BACTERIAL TOXIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR;

ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL STRAIN; BIFIDOBACTERIUM; BIFIDOBACTERIUM LONGUM; CECUM; CONTROLLED STUDY; ENTEROCOLITIS; GROWTH INHIBITION; HISTOPATHOLOGY; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; REAL TIME POLYMERASE CHAIN REACTION;

EID: 85046640452     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2018.00888     Document Type: Article

References (60)

1. Anand, R., Song, Y., Garg, S., Girotra, M., Sinha, A., Sivaraman, A., et al. (2017). Effect of aging on the composition of fecal microbiota in donors for FMT and its impact on clinical outcomes. Dig. Dis. Sci. 62, 1002-1008. doi: 10.1007/s10620-017-4449-6
2. Babakhani, F., Bouillaut, L., Sears, P., Sims, C., Gomez, A., and Sonenshein, A. L. (2013). Fidaxomicin inhibits toxin production in Clostridium difficile. J. Antimicrob. Chemother. 68, 515-522. doi: 10.1093/jac/dks450
3. Badger, V. O., Ledeboer, N. A., Graham, M. B., and Edmiston, C. E. Jr. (2012). Clostridium difficile: epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen. JPEN J. Parenter. Enteral. Nutr. 36, 645-662. doi: 10.1177/0148607112446703
4. Bartlett, J. G. (2002). Clinical practice. Antibiotic-associated diarrhea. N. Engl. J. Med. 346, 334-339. doi: 10.1056/NEJMcp011603
5. Basseres, E., Endres, B. T., Khaleduzzaman, M., Miraftabi, F., Alam, M. J., Vickers, R. J., et al. (2016). Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J. Antimicrob. Chemother. 71, 1245-1251. doi: 10.1093/jac/dkv498
6. Benno, Y., and Mitsuoka, T. (1992). Impact of Bifidobacterium longum on human fecal microflora. Microbiol. Immunol. 36, 683-694. doi: 10.1111/j.1348-0421.1992.tb02071.x
7. Bolla, P. A., Carasi, P., Serradell Mde, L., and De Antoni, G. L. (2013). Kefir-isolated Lactococcus lactis subsp. lactis inhibits the cytotoxic effect of Clostridium difficile in vitro. J. Dairy Res. 80, 96-102. doi: 10.1017/S0022029912000623
8. Boonma, P., Spinler, J. K., Venable, S. F., Versalovic, J., and Tumwasorn, S. (2014). Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells. BMC Microbiol. 14:177. doi: 10.1186/1471-2180-14-177
9. Britton, R. A., and Young, V. B. (2011). Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 146, 1547-1553. doi: 10.1053/j.gastro.2014.01.059
10. Carter, G. P., Chakravorty, A., Pham Nguyen, T. A., Mileto, S., Schreiber, F., Li, L., et al. (2015). Defining the Roles of TcdA and TcdB in localized gastrointestinal disease, systemic organ damage, and the host response during Clostridium difficile infections. mBio 6:e00551-15. doi: 10.1128/mBio.00551-15
11. Carter, G. P., Douce, G. R., Govind, R., Howarth, P. M., Mackin, K. E., Spencer, J., et al. (2011). The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog. 7:e1002317. doi: 10.1371/journal.ppat.1002317
12. Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., et al. (2008). Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 197, 435-438. doi: 10.1086/525047
13. Chen, X., Katchar, K., Goldsmith, J. D., Nanthakumar, N., Cheknis, A., Gerding, D. N., et al. (2008). A mouse model of Clostridium difficile-associated disease. Gastroenterology 135, 1984-1992. doi: 10.1053/j.gastro.2008.09.002
14. Chenoll, E., Casinos, B., Bataller, E., Astals, P., Echevarria, J., Iglesias, J. R., et al. (2011). Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Appl. Environ. Microbiol. 77, 1335-1343. doi: 10.1128/AEM.01820-10
15. Darkoh, C., DuPont, H. L., Norris, S. J., and Kaplan, H. B. (2015). Toxin synthesis by Clostridium difficile is regulated through quorum signaling. mBio 6:e02569-14. doi: 10.1128/mBio.02569-14
16. Evans, C. T., and Johnson, S. (2015). Prevention of Clostridium difficile infection with probiotics. Clin. Infect. Dis. 60(Suppl. 2), S122-S128. doi: 10.1093/cid/civ138
17. Falony, G., Vlachou, A., Verbrugghe, K., and De Vuyst, L. (2006). Cross-feeding between Bifidobacterium longum BB536 and acetate-converting, butyrate-producing colon bacteria during growth on oligofructose. Appl. Environ. Microbiol. 72, 7835-7841. doi: 10.1128/AEM.01296-06
18. FAO/WHO (2001). Report on Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic acid Bacteria. Available at: https://www.mendeley.com/research-papers/health-nutritional-properties-probiotics-food-including-powder-milk-live-lactic-acid-bacteria/
19. Geeraerts, S., Ducatelle, R., Haesebrouck, F., and Van Immerseel, F. (2015). Bacillus amyloliquefaciens as prophylactic treatment for Clostridium difficile-associated disease in a mouse model. J. Gastroenterol. Hepatol. 30, 1275-1280. doi: 10.1111/jgh.12957
20. Giel, J. L., Sorg, J. A., Sonenshein, A. L., and Zhu, J. (2010). Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS One 5:e8740. doi: 10.1371/journal.pone.0008740
21. Goldenberg, J. Z., Yap, C., Lytvyn, L., Lo, C. K., Beardsley, J., Mertz, D., et al. (2017). Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst. Rev. 12:CD006095. doi: 10.1002/14651858.CD006095.pub4
22. Grazul, H., Kanda, L. L., and Gondek, D. (2016). Impact of probiotic supplements on microbiome diversity following antibiotic treatment of mice. Gut Microbes 7, 101-114. doi: 10.1080/19490976.2016.1138197
23. Hirota, S. A., Iablokov, V., Tulk, S. E., Schenck, L. P., Becker, H., Nguyen, J., et al. (2012). Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure. Infect. Immun. 80, 4474-4484. doi: 10.1128/IAI.00933-12
24. Hudson, L. E., Anderson, S. E., Corbett, A. H., and Lamb, T. J. (2017). Gleaning insights from fecal microbiota transplantation and probiotic studies for the rational design of combination microbial therapies. Clin. Microbiol. Rev. 30, 191-231. doi: 10.1128/CMR.00049-16
25. Jeon, S. G., Kayama, H., Ueda, Y., Takahashi, T., Asahara, T., Tsuji, H., et al. (2012). Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog. 8:e1002714. doi: 10.1371/journal.ppat.1002714
26. Juszczuk, K., Grudlewska, K., Mikucka, A., and Gospodarek, E. (2017). Fecal microbiota transplantation-methods of treatment of recurrent Clostridium difficile infections and other diseases. Postepy Hig. Med. Dosw. 71, 220-226. doi: 10.5604/01.3001.0010.3807
27. Kalil, A. C., and Schooneveld, T. C. (2014). Probiotics and antibiotic-associated diarrhoea. Lancet 383, 29-30. doi: 10.1016/S0140-6736(13)62734-8
28. Kang, J. K., Hwang, J. S., Nam, H. J., Ahn, K. J., Seok, H., Kim, S. K., et al. (2011). The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity. Antimicrob. Agents Chemother. 55, 4850-4857. doi: 10.1128/AAC.00177-11
29. Kim, H., Rhee, S. H., Pothoulakis, C., and Lamont, J. T. (2007). Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 up-regulation of Fas ligand. Gastroenterology 133, 875-886. doi: 10.1053/j.gastro.2007.06.063
30. Kociolek, L. K., and Gerding, D. N. (2016). Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat. Rev. Gastroenterol. Hepatol. 13, 150-160. doi: 10.1038/nrgastro.2015.220
31. Kumar, M., Dhaka, P., Vijay, D., Vergis, J., Mohan, V., Kumar, A., et al. (2016). Antimicrobial effects of Lactobacillus plantarum and Lactobacillus acidophilus against multidrug-resistant enteroaggregative Escherichia coli. Int. J. Antimicrob. Agents 48, 265-270. doi: 10.1016/j.ijantimicag.2016.05.014
32. Lee, I. A., Bae, E. A., Lee, J. H., Lee, H., Ahn, Y. T., Huh, C. S., et al. (2009). Bifidobacterium longum HY8004 attenuates TNBS-induced colitis by inhibiting lipid peroxidation in mice. Inflamm. Res. 59, 359-368. doi: 10.1007/s00011-009-0108-5
33. Leslie, J. L., Huang, S., Opp, J. S., Nagy, M. S., Kobayashi, M., Young, V. B., et al. (2015). Persistence and toxin production by Clostridium difficile within human intestinal organoids result in disruption of epithelial paracellular barrier function. Infect. Immun. 83, 138-145. doi: 10.1128/IAI.02561-14
34. Li, Y., Figler, R. A., Kolling, G., Bracken, T. C., Rieger, J., Stevenson, R. W., et al. (2012). Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment. BMC Infect. Dis. 12:342. doi: 10.1186/1471-2334-12-342
35. Louh, I. K., Greendyke, W. G., Hermann, E. A., Davidson, K. W., Falzon, L., Vawdrey, D. K., et al. (2017). Clostridium Difficile infection in acute care hospitals: systematic review and best practices for prevention. Infect. Control Hosp. Epidemiol. 38, 476-482. doi: 10.1017/ice.2016.324
36. Mani, N., and Dupuy, B. (2001). Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc. Natl. Acad. Sci. U.S.A. 98, 5844-5849. doi: 10.1073/pnas.101126598
37. McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C. Jr., Kazakova, S. V., Kazakova, S. V., et al. (2005). An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353, 2433-2441. doi: 10.1056/NEJMoa051590
38. Meli, F., Lazzi, C., Neviani, E., and Gatti, M. (2013). Effect of protein hydrolizates on growth kinetics and aminopeptidase activities of some Bifidobacterium species. Anaerobe 22, 130-133. doi: 10.1016/j.anaerobe.2013.05.003
39. Mills, J. P., Rao, K., and Young, V. B. (2018). Probiotics for prevention of Clostridium difficile infection. Curr. Opin. Gastroenterol. 34, 3-10. doi: 10.1097/MOG.0000000000000410
40. Munoz, J. A., Chenoll, E., Casinos, B., Bataller, E., Ramon, D., Genoves, S., et al. (2011). Novel probiotic Bifidobacterium longum subsp. infantis CECT 7210 strain active against rotavirus infections. Appl. Environ. Microbiol. 77, 8775-8783. doi: 10.1128/AEM.05548-11
41. Munoz-Quezada, S., Bermudez-Brito, M., Chenoll, E., Genoves, S., Gomez-Llorente, C., Plaza-Diaz, J., et al. (2013). Competitive inhibition of three novel bacteria isolated from faeces of breast milk-fed infants against selected enteropathogens. Br. J. Nutr. 109(Suppl. 2), S63-S69. doi: 10.1017/S0007114512005600
42. Parkes, G. C., Sanderson, J. D., and Whelan, K. (2009). The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. Lancet Infect. Dis. 9, 237-244. doi: 10.1016/S1473-3099(09)70059-3
43. Petrosillo, N. (2018). Tackling the recurrence of Clostridium difficile infection. Med. Mal. Infect. 48, 18-22. doi: 10.1016/j.medmal.2017.10.007
44. Pothoulakis, C., Kelly, C. P., Joshi, M. A., Gao, N., O'Keane, C. J., Castagliuolo, I., et al. (1993). Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 104, 1108-1115. doi: 10.1016/0016-5085(93)90280-P
45. Ratsep, M., Koljalg, S., Sepp, E., Smidt, I., Truusalu, K., Songisepp, E., et al. (2017). A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection. Anaerobe 47, 94-103. doi: 10.1016/j.anaerobe.2017.03.019
46. Ripert, G., Racedo, S. M., Elie, A. M., Jacquot, C., Bressollier, P., and Urdaci, M. C. (2016). Secreted compounds of the probiotic Bacillus clausii strain O/C inhibit the cytotoxic effects induced by Clostridium difficile and Bacillus cereus toxins. Antimicrob. Agents Chemother. 60, 3445-3454. doi: 10.1128/AAC.02815-15
47. Rolfe, R. D. (2000). The role of probiotic cultures in the control of gastrointestinal health. J. Nutr. 130(2S Suppl.), 396S-402S. doi: 10.1093/jn/130.2.396S
48. Rupnik, M., Wilcox, M. H., and Gerding, D. N. (2009). Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7, 526-536. doi: 10.1038/nrmicro2164
49. Schoster, A., Kokotovic, B., Permin, A., Pedersen, P. D., Dal Bello, F., and Guardabassi, L. (2013). In vitro inhibition of Clostridium difficile and Clostridium perfringens by commercial probiotic strains. Anaerobe 20, 36-41. doi: 10.1016/j.anaerobe.2013.02.006
50. Sheu, S. J., Hwang, W. Z., Chiang, Y. C., Lin, W. H., Chen, H. C., and Tsen, H. Y. (2010). Use of tuf gene-based primers for the PCR detection of probiotic Bifidobacterium species and enumeration of bifidobacteria in fermented milk by cultural and quantitative real-time PCR methods. J. Food Sci. 75,M521-M527. doi: 10.1111/j.1750-3841.2010.01816.x
51. Spinler, J. K., Auchtung, J., Brown, A., Boonma, P., Oezguen, N., Ross, C. L., et al. (2017). Next-generation probiotics targeting Clostridium difficile through precursor-directed antimicrobial biosynthesis. Infect. Immun. 85:e00303-17. doi: 10.1128/IAI.00303-17
52. Trejo, F. M., De Antoni, G. L., and Perez, P. F. (2013). Protective effect of bifidobacteria in an experimental model of Clostridium difficile associated colitis. J. Dairy Res. 80, 263-269. doi: 10.1017/S0022029913000216
53. Trejo, F. M., Perez, P. F., and De Antoni, G. L. (2010). Co-culture with potentially probiotic microorganisms antagonises virulence factors of clostridium difficile in vitro. Antonie Van Leeuwenhoek 98, 19-29. doi: 10.1007/s10482-010-9424-6
54. Valdes-Varela, L., Alonso-Guervos, M., Garcia-Suarez, O., Gueimonde, M., and Ruas-Madiedo, P. (2016). Screening of Bifidobacteria and Lactobacilli able to antagonize the cytotoxic effect of Clostridium difficile upon intestinal epithelial HT29 monolayer. Front. Microbiol. 7:577. doi: 10.3389/fmicb.2016.00577
55. Vemuri, R. C., Gundamaraju, R., Shinde, T., and Eri, R. (2017). Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation? Benef. Microbes 8, 179-192. doi: 10.3920/BM2016.0115
56. Wei, Y., Li, Y., Yang, F., Wu, Q., Liu, D., Li, X., et al. (2017). Physical and functional interplay between MazF1Bif and its noncognate antitoxins from Bifidobacterium longum. Appl. Environ. Microbiol. 83:e03232-16. doi: 10.1128/AEM.03232-16
57. Wei, Y. X., Zhang, Z. Y., Liu, C., Zhu, Y. Z., Zhu, Y. Q., Zheng, H., et al. (2010). Complete genome sequence of Bifidobacterium longum JDM301. J. Bacteriol. 192, 4076-4077. doi: 10.1128/JB.00538-10
58. Xu, H., Jeong, H. S., Lee, H. Y., and Ahn, J. (2009). Assessment of cell surface properties and adhesion potential of selected probiotic strains. Lett. Appl. Microbiol. 49, 434-442. doi: 10.1111/j.1472-765X.2009.02684.x
59. Yang, J., Zhang, H., Jiang, L., Guo, H., Luo, X., and Ren, F. (2015). Bifidobacterium longum BBMN68-specific modulated dendritic cells alleviate allergic responses to bovine beta-lactoglobulin in mice. J. Appl. Microbiol. 119, 1127-1137. doi: 10.1111/jam.12923
60. Yun, B., Song, M., Park, D. J., and Oh, S. (2017). Beneficial effect of Bifidobacterium longum ATCC 15707 on survival rate of Clostridium difficile infection in mice. Korean J. Food Sci. Anim. Resour. 37, 368-375. doi: 10.5851/kosfa.2017.37.3.368